Transitioning from intravenous to subcutaneous ocrelizumab in a high-volume infusion center: A time-and-motion-informed capacity and service-flow analysis.
Zanghì A, Di Filippo P S, Rutigliano C, Moretti M C, Avolio C, D'Amico E
Mult Scler Relat Disord. 2026 May 24; 112:107267. PMID: 42259159.Abstract
